Antioxidant mechanisms in nonalcoholic fatty liver disease

Current Drug Targets

Volumn 16, Issue 12, 2015, Pages 1301-1314

  Liu, Wensheng ^a   Baker, Susan S ^a   Baker, Robert D ^a   Zhu, Lixin ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Alcohol metabolism; Antioxidant; Fatty acid oxidation; Lipid metabolism; NAFLD; NASH; Oxidative stress; Reactive oxygen species

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HEMOGLOBIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REACTIVE OXYGEN METABOLITE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPEROXIDE DISMUTASE; THIOREDOXIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; XANTHINE OXIDASE; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE;

ALCOHOL METABOLISM; ANTIOXIDANT ACTIVITY; ARTICLE; HUMAN; IMMUNOFLUORESCENCE; INSULIN RESISTANCE; LIPID HOMEOSTASIS; LIPID METABOLISM; LIPOGENESIS; LIPOTOXICITY; METABOLIC SYNDROME X; MITOCHONDRIAL RESPIRATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CATALASE; GLUTATHIONE; HUMANS; LIPID METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE;

EID: 84937590608     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150427155342     Document Type: Article

References (190)

1. [1] Yoon HJ, Cha BS. Pathogenesis and therapeutic approaches fornon-alcoholic fatty liver disease. World J Hepatol 2014; 6(11):800-11.
2. [2] Gambino R, Musso G, Cassader M. Redox balance in the pathogenesisof nonalcoholic fatty liver disease: mechanisms and therapeuticopportunities. Antioxid Redox Signal 2011; 15(5): 1325-65.
3. [3] Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidativestress, cardiolipin and mitochondrial dysfunction in nonalcoholicfatty liver disease. World J Gastroenterol 2014; 20(39): 14205-18.
4. [4] Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis:epidemiology, pathogenesis, clinical presentation and treatment.Dig Dis 2012; 30(2): 158-62.
5. [5] Vernon G, Baranova A, Younossi ZM. Systematic review: theepidemiology and natural history of non-alcoholic fatty liver diseaseand non-alcoholic steatohepatitis in adults. Aliment PharmacolTher 2011; 34(3): 274-85.
6. 6] Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver. epidemiology and natural history. RevRecent Clin Trials 2014; 9(3): 126-33.
7. 7] Almeda-Valdes P, Aguilar-Olivos N, Uribe M, Mendez-Sanchez N.Common features of the metabolic syndrome and nonalcoholicfatty liver disease. Rev Recent Clin Trials 2014; 9(3): 14-8.
8. 8] Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346(16): 1221-31.
9. 9] Widmer CC, Pereira CP, Gehrig P, et al. Hemoglobin can attenuatehydrogen peroxide-induced oxidative stress by acting as an antioxidativeperoxidase. Antioxid Redox Signal 2010; 12(2): 185-98.
10. 10] Liu W, Baker SS, Baker RD, Nowak NJ, Zhu L. Upregulation ofhemoglobin expression by oxidative stress in hepatocytes and itsimplication in nonalcoholic steatohepatitis. PLoS One 2011; 6(9):e24363.
11. 11] Kang JH. Modification and inactivation of Cu, Zn-superoxidedismutase by the lipid peroxidation product, acrolein. BMB Rep2013; 46(11): 555-60.
12. 12] Vessey DA, Lee KH. Inactivation of enzymes of the glutathioneantioxidant system by treatment of cultured human keratinocyteswith peroxides. J Invest Dermatol 1993; 100(6): 829-33.
13. 13] Pigeolet E, Corbisier P, Houbion A, et al. Glutathione peroxidase,superoxide dismutase, and catalase inactivation by peroxides andoxygen derived free radicals. Mech Ageing Dev 1990; 51(3): 283-97.
14. 14] Bray RC, Cockle SA, Fielden EM, Roberts PB, Rotilio G, Calabrese L. Reduction and inactivation of superoxide dismutase byhydrogen peroxide. Biochem J 1974; 139(1): 43-8.
15. 15] Desai S, Baker SS, Liu W, et al. Paraoxonase 1 and oxidative stressin paediatric non-alcoholic steatohepatitis. Liver Int 2014; 34(1):110-7.
16. 16] Zeng L, Tang WJ, Yin JJ, Zhou BJ. Signal transductions and nonalcoholicfatty liver: a mini-review. Int J Clin Exp Med 2014; 7(7):1624-31.
17. 17] Paredes AH, Torres DM, Harrison SA. Nonalcoholic fatty liverdisease. Clin Liver Dis 2012; 16(2): 397-419.
18. 18] Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an inflammatorydisorder: pathogenic, prognostic and therapeutic implications.Gut Liver 2012; 6(2): 149-71.
19. 19] Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenicduo. Endocr Rev 2013; 34(1): 84-129.
20. 20] Matherly SC, Puri P. Mechanisms of simple hepatic steatosis: notso simple after all. Clin Liver Dis 2012; 16(3): 505-24.
21. 21] Bohinc BN, Diehl AM. Mechanisms of disease progression inNASH: new paradigms. Clin Liver Dis 2012; 16(3): 549-65.
22. 22] Cusi K. Role of obesity and lipotoxicity in the development ofnonalcoholic steatohepatitis: pathophysiology and clinical implications.Gastroenterology 2012; 142(4): 711-25.e6.
23. 23] Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: oldquestions and new insights. Science 2011; 332(6037): 1519-23.
24. 24] Tilg H, Moschen AR. Evolution of inflammation in nonalcoholicfatty liver disease: the multiple parallel hits hypothesis. Hepatology2010; 52(5): 1836-46.
25. 25] Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease:pathology and pathogenesis. Annu Rev Pathol 2010; 5: 145-71.
26. 26] Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASHpathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol2010; 25(4): 672-90.
27. 27] Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of nonalcoholicfatty liver disease. QJM 2010; 103(2): 71-83.
28. 28] Anderson N, Borlak J. Molecular mechanisms and therapeutictargets in steatosis and steatohepatitis. Pharmacol Rev 2008; 60(3):311-57.
29. 29] Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholicsteatohepatitis. Trends Mol Med 2008; 14(2): 72-81.
30. 30] Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesisof nonalcoholic steatohepatitis: the central role of nontriglyceridefatty acid metabolites. Hepatology 2010; 52(2): 774-88.
31. 31] Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted vialipoproteins in patients with nonalcoholic fatty liver disease. J ClinInvest 2005; 115(5): 1343-51.
32. 32] Diraison F, Beylot M. Role of human liver lipogenesis and reesterificationin triglycerides secretion and in FFA reesterification. Am JPhysiol 1998; 274(2 Pt 1): E321-7.
33. 33] Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholicsteatohepatitis: association of insulin resistance and mitochondrialabnormalities. Gastroenterology 2001; 120(5): 1183-92.
34. 34] Miele L, Grieco A, Armuzzi A, et al. Hepatic mitochondrial betaoxidationin patients with nonalcoholic steatohepatitis assessed by13C-octanoate breath test. Am J Gastroenterol 2003; 98(10): 2335-6.
35. 35] Koek GH, Liedorp PR, Bast A. The role of oxidative stress in nonalcoholicsteatohepatitis. Clin Chim Acta 2011; 412(15-16): 1297-305.
36. 36] Gonzalez FJ, Peters JM, Cattley RC. Mechanism of action of thenongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J Natl Cancer Inst 1998; 90(22):1702-9.
37. 37] Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholicsteatohepatitis. Hepatology 1998; 27(1): 128-33.
38. 38] Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochromeP450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis.Hepatology 2003; 37(3): 544-50.
39. 39] Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis andsteatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress.Am J Physiol Gastrointest Liver Physiol 2001; 281(5): G1135-9.
40. 40] Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol2002; 16(5): 663-78.
41. 41] Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomalbeta-oxidation, PPAR alpha, and steatohepatitis. Am JPhysiol Gastrointest Liver Physiol 2001; 281(6): G1333-9.
42. 42] Musso G, Gambino R, Durazzo M, et al. Adipokines in NASH:postprandial lipid metabolism as a link between adiponectin andliver disease. Hepatology 2005; 42(5): 1175-83.
43. 43] Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kineticsin obese men and women with nonalcoholic fatty liver disease.Gastroenterology 2008; 134(2): 424-31.
44. 44] Zhu L, Baker SS, Liu W, et al. Lipid in the livers of adolescentswith nonalcoholic steatohepatitis: combined effects of pathways onsteatosis. Metabolism 2011; 60(7): 1001-11.
45. 45] Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependentdiabetes mellitus of obese rats: impairment in adipocyte-beta-cellrelationships. Proc Natl Acad Sci USA 1994; 91(23): 10878-82.
46. 46] Zambo V, Simon-Szabo L, Szelenyi P, Kereszturi E, Banhegyi G, Csala M. Lipotoxicity in the liver. World J Hepatol 2013; 5(10):550-7.
47. 47] Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholicfatty liver disease: not all lipids are created equal. Expert Rev GastroenterolHepatol 2009; 3(4): 445-51.
48. 48] Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans2007; 35(Pt 5): 1147-50.
49. 49] Mittler R, Vanderauwera S, Suzuki N, et al. ROS signaling: thenew wave? Trends Plant Sci 2011; 16(6): 300-9.
50. 50] D'Autreaux B, Toledano MB. ROS as signalling molecules:mechanisms that generate specificity in ROS homeostasis. Nat RevMol Cell Biol 2007; 8(10): 813-24.
51. 51] Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and newtreatment strategies for non-alcoholic steatohepatitis (NASH). Int JMol Sci 2014; 15(5): 7352-79.
52. 52] Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in thepathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med2012; 52(1): 59-69.
53. 53] Brand MD. The sites and topology of mitochondrial superoxideproduction. Exp Gerontol 2010; 45(7-8): 466-72.
54. 54] Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, RobertsonGR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxidesin murine nonalcoholic steatohepatitis. J Clin Invest 2000;105(8): 1067-75.
55. [55] Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrialdysfunction in NASH: causes, consequences and possible means toprevent it. Mitochondrion 2006; 6(1): 1-28.
56. [56] Sakaguchi S, Takahashi S, Sasaki T, Kumagai T, Nagata K. Progressionof alcoholic and non-alcoholic steatohepatitis: commonmetabolic aspects of innate immune system and oxidative stress.Drug Metab Pharmacokinet 2011; 26(1): 30-46.
57. [57] Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM.Mitochondrial dysfunction and oxidative stress in the pathogenesisof alcohol- and obesity-induced fatty liver diseases. Free RadicBiol Med 2008; 44(7): 1259-72.
58. [58] Sarkola T, Eriksson CJ. Effect of 4-methylpyrazole on endogenousplasma ethanol and methanol levels in humans. Alcohol Clin ExpRes 2001; 25(4): 513-6.
59. [59] Blomstrand R. Observations of the formation of ethanol in theintestinal tract in man. Life Sci II 1971; 10(10): 575-82.
60. [60] Watanabe-Suzuki K, Seno H, Ishii A, Kumazawa T, Suzuki O.Ultra-sensitive method for determination of ethanol in whole bloodby headspace capillary gas chromatography with cryogenic oventrapping. J Chromatogr B Biomed Sci Appl 1999; 727(1-2): 89-94.
61. [61] Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomesin nonalcoholic steatohepatitis (NASH) patients: a connection betweenendogenous alcohol and NASH. Hepatology 2013; 57(2):601-9.
62. [62] Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. Role of alcoholmetabolism in non-alcoholic steatohepatitis. PLoS One 2010; 5(3):e9570.
63. [63] Volynets V, Kuper MA, Strahl S, et al. Nutrition, intestinal permeability,and blood ethanol levels are altered in patients with nonalcoholicfatty liver disease (NAFLD). Dig Dis Sci 2012; 57(7):1932-41.
64. [64] Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis andsteatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. AmJ Physiol Gastrointest Liver Physiol 2002; 282(2): G193-9.
65. [65] Haque M, Sanyal AJ. The metabolic abnormalities associated withnon-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol2002; 16(5): 709-31.
66. [66] Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl A M. Alterations in liver ATP homeostasis in human nonalcoholicsteatohepatitis: a pilot study. Jama 1999; 282(17): 1659-64.
67. [67] Perez-Carreras M, Hoyo PD, Martin MA, et al. Defective hepaticmitochondrial respiratory chain in patients with nonalcoholic steatohepatitis.Hepatology 2003; 38(4): 999-1007.
68. [68] Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalitiesin non-alcoholic steatohepatitis. J Hepatol 1999; 31(3):430-4.
69. [69] Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damagein non-alcoholic fatty liver diseases. J Hepatol 2002; 37(1): 56-62.
70. [70] Tanaka S, Miyanishi K, Kobune M, et al. Increased hepatic oxidativeDNA damage in patients with nonalcoholic steatohepatitis whodevelop hepatocellular carcinoma. J Gastroenterol 2013; 48(11):1249-58.
71. [71] Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. Diversity in antioxidant response enzymes in progressive stages ofhuman nonalcoholic fatty liver disease. Drug Metab Dispos 2010;38(12): 2293-301.
72. [72] Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M.Heme oxygenase-1 levels and oxidative stress-related parameters innon-alcoholic fatty liver disease patients. J Hepatol 2005; 42(4):585-91.
73. [73] Park H, Ishigami A, Shima T, et al. Hepatic senescence markerprotein-30 is involved in the progression of nonalcoholic fatty liverdisease. J Gastroenterol 2010; 45(4): 426-34.
74. [74] Kitade M, Yoshiji H, Kojima H, et al. Neovascularization andoxidative stress in the progression of non-alcoholic steatohepatitis.Mol Med Rep 2008; 1(4): 543-8.
75. [75] Seki S, Kitada T, Sakaguchi H. Clinicopathological significance ofoxidative cellular damage in non-alcoholic fatty liver diseases. HepatolRes 2005; 33(2): 132-4.
76. [76] Oliveira CP, Faintuch J, Rascovski A, et al. Lipid peroxidation inbariatric candidates with nonalcoholic fatty liver disease (NAFLD)-- preliminary findings. Obes Surg 2005; 15(4): 502-5.
77. [77] Perlemuter G, Davit-Spraul A, Cosson C, et al. Increase in liverantioxidant enzyme activities in non-alcoholic fatty liver disease.Liver Int 2005; 25(5): 946-53.
78. [78] Piemonte F, Petrini S, Gaeta LM, et al. Protein glutathionylationincreases in the liver of patients with non-alcoholic fatty liver disease.J Gastroenterol Hepatol 2008; 23(8 Pt 2): e457-64.
79. [79] Videla LA, Rodrigo R, Orellana M, et al. Oxidative stress-relatedparameters in the liver of non-alcoholic fatty liver disease patients.Clin Sci (Lond) 2004; 106(3): 261-8.
80. [80] Kojima H, Sakurai S, Uemura M, Fukui H, Morimoto H, TamagawaY. Mitochondrial abnormality and oxidative stress in nonalcoholicsteatohepatitis. Alcohol Clin Exp Res 2007; 31(Suppl 1):S61-6.
81. [81] Irie M, Sohda T, Iwata K, et al. Levels of the oxidative stressmarker gamma-glutamyltranspeptidase at different stages of nonalcoholicfatty liver disease. J Int Med Res 2012; 40(3): 924-33.
82. [82] Fujita N, Miyachi H, Tanaka H, et al. Iron overload is associatedwith hepatic oxidative damage to DNA in nonalcoholic steatohepatitis.Cancer Epidemiol Biomarkers Prev 2009; 18(2): 424-32.
83. [83] Nomoto K, Tsuneyama K, Takahashi H, Murai Y, Takano Y. Cytoplasmicfine granular expression of 8-hydroxydeoxyguanosine reflectsearly mitochondrial oxidative DNA damage in nonalcoholicfatty liver disease. Appl Immunohistochem Mol Morphol 2008;16(1): 71-5.
84. [84] Takahashi Y, Kobayashi Y, Kawata K, et al. Does hepatic oxidativestress enhance activation of nuclear factor-E2-related factor inpatients with nonalcoholic steatohepatitis? Antioxid Redox Signal2014; 20(3): 538-43.
85. [85] Nobili V, Parola M, Alisi A, et al. Oxidative stress parameters inpaediatric non-alcoholic fatty liver disease. Int J Mol Med 2010;26(4): 471-6.
86. [86] Georgoulis M, Fragopoulou E, Kontogianni MD, et al. Blood redoxstatus is associated with the likelihood of nonalcoholic fatty liverdisease irrespectively of diet's total antioxidant capacity. Nutr Res2015; 35(1): 41-8.
87. [87] Narasimhan S, Gokulakrishnan K, Sampathkumar R, et al. Oxidativestress is independently associated with non-alcoholic fatty liverdisease (NAFLD) in subjects with and without type 2 diabetes. ClinBiochem 2010; 43(10-11): 815-21.
88. [88] Das KS, Balakrishnan V, Mukherjee S, Vasudevan DM. Evaluationof blood oxidative stress-related parameters in alcoholic liver diseaseand non-alcoholic fatty liver disease. Scand J Clin Lab Invest2008; 68(4): 323-34.
89. [89] Bhardwaj P, Madan K, Thareja S, Joshi YK, Saraya A. Comparativeredox status in alcoholic liver disease and nonalcoholic fattyliver disease. Hepatol Int 2008; 2(2): 202-8.
90. [90] Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A. Oxidantstress and antioxidant status among patients with nonalcoholic fattyliver disease (NAFLD). J Clin Gastroenterol 2006; 40(10): 930-5.
91. [91] Saricam T, Kircali B, Koken T. Assessment of lipid peroxidationand antioxidant capacity in non-alcoholic fatty liver disease. Turk JGastroenterol 2005; 16(2): 65-70.
92. [92] Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidationand its metabolic and dietary correlates in patients withnonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99(8):1497-502.
93. [93] Leach NV, Dronca E, Vesa SC, et al. Serum homocysteine levels,oxidative stress and cardiovascular risk in non-alcoholic steatohepatitis.Eur J Intern Med 2014; 25(8): 762-7.
94. [94] Bessa SS, Ali EMM, Ael SAE, El-Din SAN. Heme oxygenase-1mRNA expression in egyptian patients with chronic liver disease.Hepat Mon 2012; 12(4): 278-85.
95. [95] Al-Gayyar MM, Shams ME, Barakat EA. Fish oil improves lipidmetabolism and ameliorates inflammation in patients with metabolicsyndrome: impact of nonalcoholic fatty liver disease. PharmBiol 2012; 50(3): 297-303.
96. [96] Uysal S, Armutcu F, Aydogan T, Akin K, Ikizek M, Yigitoglu MR. Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. ClinBiochem 2011; 44(17-18): 1375-9.
97. [97] Samy W, Hassanian MA. Paraoxonase-1 activity, malondialdehydeand glutathione peroxidase in non-alcoholic fatty liver disease andthe effect of atorvastatin. Arab J Gastroenterol 2011; 12(2): 80-5.
98. [98] Yesilova Z, Yaman H, Oktenli C, et al. Systemic markers of lipidperoxidation and antioxidants in patients with nonalcoholic Fattyliver disease. Am J Gastroenterol 2005; 100(4): 850-5.
99. [99] Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M.Oxidative stress and enzymatic antioxidant status in patients withnonalcoholic steatohepatitis. Ann Clin Lab Sci 2004; 34(1): 57-62.
100. [100] Baskol M, Baskol G, Deniz K, Ozbakir O, Yucesoy M. A newmarker for lipid peroxidation: serum paraoxonase activity in nonalcoholicsteatohepatitis. Turk J Gastroenterol 2005; 16(3): 119-23.
101. [101] Canbakan B, Senturk H, Canbakan M, et al. Is alanine aminotransferaselevel a surrogate biomarker of hepatic apoptosis in nonalcoholicfatty liver disease? Biomark Med 2010; 4(2): 205-14.
102. [102] Torer N, Ozenirler S, Yucel A, Bukan N, Erdem O. Importance ofcytokines, oxidative stress and expression of BCL-2 in the pathogenesisof non-alcoholic steatohepatitis. Scand J Gastroenterol2007; 42(9): 1095-101.
103. [103] Albano E, Mottaran E, Vidali M, et al. Immune response towardslipid peroxidation products as a predictor of progression of nonalcoholicfatty liver disease to advanced fibrosis. Gut 2005; 54(7):987-93.
104. [104] Machado MV, Ravasco P, Jesus L, et al. Blood oxidative stressmarkers in non-alcoholic steatohepatitis and how it correlates withdiet. Scand J Gastroenterol 2008; 43(1): 95-102.
105. [105] Feldstein AE, Lopez R, Tamimi TA, et al. Mass spectrometricprofiling of oxidized lipid products in human nonalcoholic fattyliver disease and nonalcoholic steatohepatitis. J Lipid Res 2010;51(10): 3046-54.
106. [106] Elizondo A, Araya J, Rodrigo R, et al. Polyunsaturated fatty acidpattern in liver and erythrocyte phospholipids from obese patients.Obesity (Silver Spring) 2007; 15(1): 24-31.
107. [107] Konishi M, Iwasa M, Araki J, et al. Increased lipid peroxidation inpatients with non-alcoholic fatty liver disease and chronic hepatitisC as measured by the plasma level of 8-isoprostane. J GastroenterolHepatol 2006; 21(12): 1821-5.
108. [108] Ben MD, Polimeni L, Carnevale R, et al. NOX2-generated oxidativestress is associated with severity of ultrasound liver steatosis inpatients with non-alcoholic fatty liver disease. BMC Gastroenterol2014; 14 81.
109. [109] Alkhouri N, Berk M, Yerian L, et al. OxNASH score correlateswith histologic features and severity of nonalcoholic fatty liver disease.Dig Dis Sci 2014; 59(7): 1617-24.
110. [110] Liu S, Shi W, Li G, et al. Plasma reactive carbonyl species levelsand risk of non-alcoholic fatty liver disease. J Gastroenterol Hepatol2011; 26(6): 1010-5.
111. [111] Musso G, Gambino R, De Michieli F, et al. Nitrosative stress predictsthe presence and severity of nonalcoholic fatty liver at differentstages of the development of insulin resistance and metabolicsyndrome: possible role of vitamin A intake. Am J Clin Nutr 2007;86(3): 661-71.
112. [112] Torun E, Gokce S, Ozgen IT, Aydin S, Cesur Y. Serum paraoxonaseactivity and oxidative stress and their relationship withobesity-related metabolic syndrome and non-alcoholic fatty liverdisease in obese children and adolescents. J Pediatr Endocrinol Metab2014; 27(7-8): 667-75.
113. [113] Imatoh T, Kamimura S, Tanihara S. Moderate oxidative stress andhigh antioxidative activity are associated with steatosis in Japanesemales. Clin Transl Sci 2013; 6(1): 45-9.
114. [114] Pirgon O, Bilgin H, Cekmez F, Kurku H, Dundar BN. Associationbetween insulin resistance and oxidative stress parameters in obeseadolescents with non-alcoholic fatty liver disease. J Clin Res PediatrEndocrinol 2013; 5(1): 33-9.
115. [115] Kumar R, Prakash S, Chhabra S, et al. Association of proinflammatorycytokines, adipokines & oxidative stress with insulinresistance & non-alcoholic fatty liver disease. Indian J Med Res2012; 136(2): 229-36.
116. [116] Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidantdefenses in serum of patients with non-alcoholic steatohepatitis.Clin Biochem 2007; 40(11): 776-80.
117. [117] Rohrdanz E, Kahl R. Alterations of antioxidant enzyme expressionin response to hydrogen peroxide. Free Radic Biol Med 1998;24(1): 27-38.
118. [118] Moya D, Baker SS, Liu W, et al. Novel pathway for iron deficiencyin pediatric non-alcoholic steatohepatitis. Clin Nutr 2015; 34(3):549-56.
119. [119] Sentman ML, Granstrom M, Jakobson H, Reaume A, Basu S, Marklund SL. Phenotypes of mice lacking extracellular superoxidedismutase and copper- and zinc-containing superoxide dismutase. JBiol Chem 2006; 281(11): 6904-9.
120. [120] Muller FL, Song W, Liu Y, et al. Absence of CuZn superoxidedismutase leads to elevated oxidative stress and acceleration ofage-dependent skeletal muscle atrophy. Free Radic Biol Med 2006;40(11): 1993-2004.
121. [121] Elchuri S, Oberley TD, Qi W, et al. CuZnSOD deficiency leads topersistent and widespread oxidative damage and hepatocarcinogenesislater in life. Oncogene 2005; 24(3): 367-80.
122. [122] Li Y, Huang TT, Carlson EJ, et al. Dilated cardiomyopathy andneonatal lethality in mutant mice lacking manganese superoxidedismutase. Nat Genet 1995; 11(4): 376-81.
123. [123] Namikawa C, Shu-Ping Z, Vyselaar JR, et al. Polymorphisms ofmicrosomal triglyceride transfer protein gene and manganese superoxidedismutase gene in non-alcoholic steatohepatitis. J Hepatol2004; 40(5): 781-6.
124. [124] Huang YS, Chang CH, Lin TL, Perng CL. Genetic variations ofsuperoxide dismutase 2 and cytochrome P450 2E1 in non-alcoholicsteatohepatitis. Liver Int 2014; 34(6): 931-6.
125. [125] Al-Serri A, Anstee QM, Valenti L, et al. The SOD2 C47T polymorphisminfluences NAFLD fibrosis severity: evidence fromcase-control and intra-familial allele association studies. J Hepatol2012; 56(2): 448-54.
126. [126] Kohjima M, Enjoji M, Higuchi N, et al. Re-evaluation of fatty acidmetabolism-related gene expression in nonalcoholic fatty liver disease.Int J Mol Med 2007; 20(3): 351-8.
127. [127] Ashla AA, Hoshikawa Y, Tsuchiya H, et al. Genetic analysis ofexpression profile involved in retinoid metabolism in non-alcoholicfatty liver disease. Hepatol Res 2010; 40(6): 594-604.
128. [128] Krautbauer S, Eisinger K, Lupke M, et al. Manganese superoxidedismutase is reduced in the liver of male but not female humansand rodents with non-alcoholic fatty liver disease. Exp Mol Pathol2013; 95(3): 330-5.
129. [129] Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic geneexpression in histologically progressive nonalcoholic steatohepatitis.Hepatology 2003; 38(1): 244-51.
130. [130] Takami Y, Uto H, Tamai T, et al. Identification of a novel biomarkerfor oxidative stress induced by hydrogen peroxide in primaryhuman hepatocytes using the 2-nitrobenzenesulfenyl chlorideisotope labeling method. Hepatol Res 2010; 40(4): 438-45.
131. [131] Nobili V, Pastore A, Gaeta LM, et al. Glutathione metabolism andantioxidant enzymes in patients affected by nonalcoholic steatohepatitis.Clin Chim Acta 2005; 355(1-2): 105-11.
132. [132] Ho YS, Xiong Y, Ma W, Spector A, Ho DS. Mice lacking catalasedevelop normally but show differential sensitivity to oxidant tissueinjury. J Biol Chem 2004; 279(31): 32804-12.
133. [133] Goth L. Catalase deficiency and type 2 diabetes. Diabetes Care2008; 31(12): e93.
134. [134] Goth L, Lenkey A, Bigler WN. Blood catalase deficiency anddiabetes in Hungary. Diabetes Care 2001; 24(10): 1839-40.
135. [135] Lubos E, Loscalzo J, Handy DE. Glutathione peroxidase-1 inhealth and disease: from molecular mechanisms to therapeutic opportunities.Antioxid Redox Signal 2011; 15(7): 1957-97.
136. [136] Lei XG. Glutathione peroxidase-1 gene knockout on body antioxidantdefense in mice. Biofactors 2001; 14(1-4): 93-9.
137. [137] Chu FF, Doroshow JH, Esworthy RS. Expression, characterization,and tissue distribution of a new cellular selenium-dependent glutathioneperoxidase, GSHPx-GI. J Biol Chem 1993; 268(4): 2571
138. [138] Florian S, Krehl S, Loewinger M, et al. Loss of GPx2 increasesapoptosis, mitosis, and GPx1 expression in the intestine of mice.Free Radic Biol Med 2010; 49(11): 1694-702.
139. [139] Macharia M, Hassan MS, Blackhurst D, Erasmus RT, Matsha TE.The growing importance of PON1 in cardiovascular health: a review.J Cardiovasc Med (Hagerstown) 2012; 13(7): 443-53.
140. [140] La Du BN, Aviram M, Billecke S, et al. On the physiologicalrole(s) of the paraoxonases. Chem Biol Interact 1999; 119-120 379-88.
141. [141] Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidationand preserves its functions. A possible peroxidative role forparaoxonase. J Clin Invest 1998; 101(8): 1581-90.
142. [142] Mackness MI, Durrington PN, Mackness B. The role of paraoxonase1 activity in cardiovascular disease: potential for therapeuticintervention. Am J Cardiovasc Drugs 2004; 4(4): 211-7.
143. [143] Hashemi M, Bahari A, Hashemzehi N, et al. Serum paraoxonaseand arylesterase activities in Iranian patients with nonalcoholicfatty liver disease. Pathophysiology 2012; 19(2): 115-9.
144. [144] Marsillach J, Mackness B, Mackness M, et al. Immunohistochemicalanalysis of paraoxonases-1, 2, and 3 expression in normalmouse tissues. Free Radic Biol Med 2008; 45(2): 146-57.
145. [145] Mackness B, Beltran-Debon R, Aragones G, Joven J, Camps J, Mackness M. Human tissue distribution of paraoxonases 1 and 2mRNA. IUBMB Life 2010; 62(6): 480-2.
146. [146] Garcia-Heredia A, Kensicki E, Mohney RP, et al. Paraoxonase-1deficiency is associated with severe liver steatosis in mice fed ahigh-fat high-cholesterol diet: a metabolomic approach. J ProteomeRes 2013; 12(4): 1946-55.
147. [147] Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increasedmacrophage oxidative stress: studies in PON1-knockout mice. FreeRadic Biol Med 2003; 34(6): 774-84.
148. [148] Rozenberg O, Shih DM, Aviram M. Paraoxonase 1 (PON1) attenuatesmacrophage oxidative status: studies in PON1 transfectedcells and in PON1 transgenic mice. Atherosclerosis 2005;181(1): 9-18.
149. [149] Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in thepathogenesis of liver disease. World J Gastroenterol 2006; 12(46):7413-20.
150. [150] Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase(PON 1) is inactivated by oxidized low density lipoproteinand preserved by antioxidants. Free Radic Biol Med 1999;26(7-8): 892-904.
151. [151] Koury MJ, Sawyer ST, Brandt SJ. New insights into erythropoiesis.Curr Opin Hematol 2002; 9(2): 93-100.
152. [152] Schechter AN. Hemoglobin research and the origins of molecularmedicine. Blood 2008; 112(10): 3927-38.
153. [153] Tsiftsoglou AS, Vizirianakis IS, Strouboulis J. Erythropoiesis:model systems, molecular regulators, and developmental programs.IUBMB Life 2009; 61(8): 800-30.
154. [154] Liu L, Zeng M, Stamler JS. Hemoglobin induction in mousemacrophages. Proc Natl Acad Sci USA 1999; 96(12): 6643-7.
155. [155] Grek CL, Newton DA, Spyropoulos DD, Baatz JE. Hypoxia upregulatesexpression of hemoglobin in alveolar epithelial cells. AmJ Respir Cell Mol Biol 2011; 44(4): 439-47.
156. [156] Newton DA, Rao KM, Dluhy RA, Baatz JE. Hemoglobin is expressedby alveolar epithelial cells. J Biol Chem 2006; 281(9):5668-76.
157. [157] Bhaskaran M, Chen H, Chen Z, Liu L. Hemoglobin is expressed inalveolar epithelial type II cells. Biochem Biophys Res Commun2005; 333(4): 1348-52.
158. [158] Nishi H, Inagi R, Kato H, et al. Hemoglobin is expressed by mesangialcells and reduces oxidant stress. J Am Soc Nephrol 2008;19(8): 1500-8.
159. [159] Biagioli M, Pinto M, Cesselli D, et al. Unexpected expression ofalpha- and beta-globin in mesencephalic dopaminergic neurons andglial cells. Proc Natl Acad Sci USA 2009; 106(36): 15454-9.
160. [160] Richter F, Meurers BH, Zhu C, Medvedeva VP, Chesselet MF. Neurons express hemoglobin alpha- and beta-chains in rat and humanbrains. J Comp Neurol 2009; 515(5): 538-47.
161. [161] Schelshorn DW, Schneider A, Kuschinsky W, et al. Expression ofhemoglobin in rodent neurons. J Cereb Blood Flow Metab 2009;29(3): 585-95.
162. [162] Russo R, Zucchelli S, Codrich M, Marcuzzi F, Verde C, Gustincich S. Hemoglobin is present as a canonical alpha2beta2 tetramer indopaminergic neurons. Biochim Biophys Acta 2013; 1834(9):1939-43.
163. [163] Tezel G, Yang X, Luo C, et al. Hemoglobin expression and regulationin glaucoma: insights into retinal ganglion cell oxygenation.Invest Ophthalmol Vis Sci 2010; 51(2): 907-19.
164. [164] Tezel TH, Geng L, Lato EB, et al. Synthesis and secretion of hemoglobinby retinal pigment epithelium. Invest Ophthalmol Vis Sci2009; 50(4): 1911-9.
165. [165] Li X, Wu Z, Wang Y, Mei Q, Fu X, Han W. Characterization ofadult alpha- and beta-globin elevated by hydrogen peroxide in cervicalcancer cells that play a cytoprotective role against oxidativeinsults. PLoS One 2013; 8(1): e54342.
166. [166] Ney PA. Gene expression during terminal erythroid differentiation.Curr Opin Hematol 2006; 13(4): 203-8.
167. [167] Stamatoyannopoulos G. Control of globin gene expression duringdevelopment and erythroid differentiation. Exp Hematol 2005;33(3): 259-71.
168. [168] Trak-Smayra V, Dargere D, Noun R, et al. Serum proteomic profilingof obese patients: correlation with liver pathology and evolutionafter bariatric surgery. Gut 2009; 58(6): 825-32.
169. [169] Xu L, Xu CF, Yu CH, Miao M, Li YM. Haemoglobin and nonalcoholicfatty liver disease: further evidence from a populationbasedstudy. Gut 2009; 58(12): 1706-7.
170. [170] Saha D, Patgaonkar M, Shroff A. Hemoglobin expression in nonerythroidcells: novel or ubiquitous? 2014; 2014 803237.
171. [171] Rahaman MM, Straub AC. The emerging roles of somatic globinsin cardiovascular redox biology and beyond. Redox Biol 2013;1(1): 405-10.
172. [172] Takahashi Y, Fukusato T. Pediatric nonalcoholic fatty liver disease:overview with emphasis on histology. World J Gastroenterol 2010;16(42): 5280-5.
173. [173] Lindback SM, Gabbert C, Johnson BL, et al. Pediatric nonalcoholicfatty liver disease: a comprehensive review. Adv Pediatr 2010;57(1): 85-140.
174. [174] Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances inpediatric nonalcoholic fatty liver disease. Hepatology 2009; 50(4):1282-93.
175. [175] Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J. Clinical correlates of histopathology in pediatric nonalcoholicsteatohepatitis. Gastroenterology 2008; 135(6): 1961-71.e2.
176. [176] Schwimmer JB, Behling C, Newbury R, et al. Histopathology ofpediatric nonalcoholic fatty liver disease. Hepatology 2005; 42(3):641-9.
177. [177] Hsu E, Murray K. Is nonalcoholic fatty liver disease in children thesame disease as in adults? Clin Liver Dis 2012; 16(3): 587-98.
178. [178] Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease inchildren. Curr Opin Clin Nutr Metab Care 2010; 13(4): 397-402.
179. [179] Jorgacevic B, Mladenovic D, Ninkovic M, et al. Dynamics of oxidative/nitrosative stress in mice with methionine-choline-deficientdiet-induced nonalcoholic fatty liver disease. Hum Exp Toxicol2013; 33(7): 701-9.
180. [180] Chowdhry S, Nazmy MH, Meakin PJ, et al. Loss of Nrf2 markedlyexacerbates nonalcoholic steatohepatitis. Free Radic Biol Med2010; 48(2): 357-71.
181. [181] Caballero F, Fernandez A, Matias N, et al. Specific contribution ofmethionine and choline in nutritional nonalcoholic steatohepatitis:impact on mitochondrial S-adenosyl-L-methionine and glutathione.J Biol Chem 2010; 285(24): 18528-36.
182. [182] Pastore A, Alisi A, di Giovamberardino G, et al. Plasma levels ofhomocysteine and cysteine increased in pediatric NAFLD andstrongly correlated with severity of liver damage. Int J Mol Sci2014; 15(11): 21202-14.
183. [183] Mitsuyoshi H, Yasui K, Harano Y, et al. Analysis of hepatic genesinvolved in the metabolism of fatty acids and iron in nonalcoholicfatty liver disease. Hepatol Res 2009; 39(4): 366-73.
184. [184] Nakashima T, Sumida Y, Furutani M, et al. Elevation of serumthioredoxin levels in patients with nonalcoholic steatohepatitis. HepatolRes 2005; 33(2): 135-7.
185. [185] Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels asa predictor of steatohepatitis in patients with nonalcoholic fattyliver disease. J Hepatol 2003; 38(1): 32-8.
186. [186] Puri K, Nobili V, Melville K, et al. Serum bilirubin level is inverselyassociated with nonalcoholic steatohepatitis in children. JPediatr Gastroenterol Nutr 2013; 57(1): 114-8.
187. [187] Salomone F, Li Volti G, Rosso C, Grosso G, Bugianesi E. Unconjugatedbilirubin, a potent endogenous antioxidant, is decreased inpatients with non-alcoholic steatohepatitis and advanced fibrosis. JGastroenterol Hepatol 2013; 28(7): 1202-8.
188. [188] Tarantino G, Colao A, Capone D, et al. Circulating levels of cytochromeC, gamma-glutamyl transferase, triglycerides and unconjugatedbilirubin in overweight/obese patients with non-alcoholicfatty liver disease. J Biol Regul Homeost Agents 2011; 25(1): 47-56.
189. [189] Kumar R, Rastogi A, Maras JS, Sarin SK. Unconjugatedhyperbilirubinemia in patients with non-alcoholic fatty liverdisease: a favorable endogenous response. Clin Biochem 2012;45(3): 272-4.
190. [190] Erhardt A, Stahl W, Sies H, Lirussi F, Donner A, Haussinger D.Plasma levels of vitamin E and carotenoids are decreased in patientswith Nonalcoholic Steatohepatitis (NASH). Eur J Med Res2011; 16(2): 76-8.